Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys.

Abstract

The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends chronic symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) including glucosamine sulfate (GS) and chondroitin sulfate (CS) as first-line therapy for knee osteoarthritis (OA). Numerous studies are published on the use of SYSADOAs in OA; however, the efficacy of this class is still called into question largely due to the regulatory status, labeling and availability of these medications which differ substantially across the world. Examination of the evidence for the prescription patented crystalline GS (pCGS) formulation at a dose of 1500mg once-daily demonstrates superiority over other GS and glucosamine hydrochloride (GH) formulations and dosage regimens. Thus, the ESCEO task force advocates differentiation of prescription pCGS over other glucosamine preparations. Long-term clinical trials and real-life studies show that pCGS may delay joint structural changes, suggesting potential benefit beyond symptom control when used early in the management of knee OA. Real-life pharmacoeconomic studies demonstrate a long-term reduction in the need for additional pain analgesia and non-steroidal anti-inflammatory drugs (NSAIDs) with pCGS, with a significant reduction of over 50% in costs associated with medications, healthcare consultations and examinations over 12 months. Furthermore, treatment with pCGS for at least 12 months leads to a reduction in the need for total joint replacement for at least 5 years following treatment cessation. Thus, pCGS (1500mg od) is a logical choice to maximize clinical benefit in OA patients, with demonstrated medium-term control of pain and lasting impact on disease progression.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Support Unit in Epidemiology and Biostatistics, Department of Public Health, Epidemiology and Health Economics, University of Liège, CHU Sart Tilman, 4000 Liège, Belgium. Electronic address: olivier.bruyere@ulg.ac.be.

    ,

    Department of Rheumatology and Immunology, David Geffen School of Medicine, University of California, Los Angeles, CA.

    Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium.

    Source

    Seminars in arthritis and rheumatism 45:4 Suppl 2016 Feb pg S12-7

    MeSH

    Aged
    Chondroitin Sulfates
    Drug Therapy, Combination
    Evidence-Based Medicine
    Glucosamine
    Humans
    Middle Aged
    Musculoskeletal Pain
    Osteoarthritis, Knee
    Randomized Controlled Trials as Topic

    Pub Type(s)

    Journal Article
    Practice Guideline
    Review

    Language

    eng

    PubMed ID

    26806187

    Citation

    Bruyère, Olivier, et al. "Efficacy and Safety of Glucosamine Sulfate in the Management of Osteoarthritis: Evidence From Real-life Setting Trials and Surveys." Seminars in Arthritis and Rheumatism, vol. 45, no. 4 Suppl, 2016, pp. S12-7.
    Bruyère O, Altman RD, Reginster JY. Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S12-7.
    Bruyère, O., Altman, R. D., & Reginster, J. Y. (2016). Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. Seminars in Arthritis and Rheumatism, 45(4 Suppl), pp. S12-7. doi:10.1016/j.semarthrit.2015.11.011.
    Bruyère O, Altman RD, Reginster JY. Efficacy and Safety of Glucosamine Sulfate in the Management of Osteoarthritis: Evidence From Real-life Setting Trials and Surveys. Semin Arthritis Rheum. 2016;45(4 Suppl):S12-7. PubMed PMID: 26806187.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys. AU - Bruyère,Olivier, AU - Altman,Roy D, AU - Reginster,Jean-Yves, Y1 - 2015/12/02/ PY - 2015/10/12/received PY - 2015/11/12/revised PY - 2015/11/25/accepted PY - 2016/1/26/entrez PY - 2016/1/26/pubmed PY - 2016/12/15/medline KW - Chondroitin KW - Glucosamine KW - Knee osteoarthritis KW - Symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) SP - S12 EP - 7 JF - Seminars in arthritis and rheumatism JO - Semin. Arthritis Rheum. VL - 45 IS - 4 Suppl N2 - The European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) treatment algorithm recommends chronic symptomatic slow-acting drugs for osteoarthritis (SYSADOAs) including glucosamine sulfate (GS) and chondroitin sulfate (CS) as first-line therapy for knee osteoarthritis (OA). Numerous studies are published on the use of SYSADOAs in OA; however, the efficacy of this class is still called into question largely due to the regulatory status, labeling and availability of these medications which differ substantially across the world. Examination of the evidence for the prescription patented crystalline GS (pCGS) formulation at a dose of 1500mg once-daily demonstrates superiority over other GS and glucosamine hydrochloride (GH) formulations and dosage regimens. Thus, the ESCEO task force advocates differentiation of prescription pCGS over other glucosamine preparations. Long-term clinical trials and real-life studies show that pCGS may delay joint structural changes, suggesting potential benefit beyond symptom control when used early in the management of knee OA. Real-life pharmacoeconomic studies demonstrate a long-term reduction in the need for additional pain analgesia and non-steroidal anti-inflammatory drugs (NSAIDs) with pCGS, with a significant reduction of over 50% in costs associated with medications, healthcare consultations and examinations over 12 months. Furthermore, treatment with pCGS for at least 12 months leads to a reduction in the need for total joint replacement for at least 5 years following treatment cessation. Thus, pCGS (1500mg od) is a logical choice to maximize clinical benefit in OA patients, with demonstrated medium-term control of pain and lasting impact on disease progression. SN - 1532-866X UR - https://www.unboundmedicine.com/medline/citation/26806187/Efficacy_and_safety_of_glucosamine_sulfate_in_the_management_of_osteoarthritis:_Evidence_from_real_life_setting_trials_and_surveys_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0049-0172(15)00289-9 DB - PRIME DP - Unbound Medicine ER -